Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
about
Radiotherapy combination opportunities leveraging immunity for the next oncology practiceImmune checkpoint inhibitors: therapeutic advances in melanomaPathways and therapeutic targets in melanomaTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsCD40 immunotherapy for pancreatic cancerImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationMechanical disruption of tumors by iron particles and magnetic field application results in increased anti-tumor immune responsesPathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancerInhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signalingComparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responsesEngulfing tumors with synthetic extracellular matrices for cancer immunotherapyCD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humansControl of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cellsIndirect recruitment of a CD40 signaling pathway in dendritic cells by B7-DC cross-linking antibody modulates T cell functions.Antibody Therapies in Cancer.Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trialA novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.The use of immunotherapy in the treatment of melanomaMolecular pathways and therapeutic targets in lung cancerActivation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironmentCD40 signaling to the rescue: A CD8 exhaustion perspective in chronic infectious diseasesActivation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand.Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations.Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters.Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancersGene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphomaAssociation of CD40 gene polymorphisms with sporadic breast cancer in Chinese Han women of Northeast China.ProtEx technology for the generation of novel therapeutic cancer vaccinesCombined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.CD1d-based combination therapy eradicates established tumors in mice.CD1d activation and blockade: a new antitumor strategyAnti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula.Targeting CD8+ T-cell tolerance for cancer immunotherapy.Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapiesEnhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.New Immunotherapy Strategies in Breast Cancer.
P2860
Q26738443-E6A672E1-99E0-4A79-946F-3D501F60A295Q26775591-51383B34-0406-4F8A-954E-4CA4406CEC17Q26865736-E8FBF5C8-45D2-4795-A13D-FD8B378F8A85Q26996518-CA187843-69CE-4FB8-8F2A-690547811BDFQ27012550-3A86104F-DDDD-437E-A0EB-3A987406328BQ28068378-B828B54B-62AB-4F4D-BB3C-A960B06F8CD7Q28390368-25BE09C0-A77E-4510-ADC8-1D4D4DA24C9AQ28392626-72289881-621E-4C0B-B066-2BDDE86EB971Q28474092-C3C34BF8-68B8-4494-B0CE-07B5455AEE47Q28507643-DCECB7F8-8318-4D47-8931-8B7CDAE608DCQ28749647-8694151A-08E5-45ED-B351-ADB9C10EA588Q29614348-005A10CC-CF31-40AF-9C9E-D98A573B375FQ30430481-AC35C342-88B9-4AE6-A52E-113A5D61E500Q30862052-05FA11CC-1507-4C4B-B229-74C9C8A55DB3Q31104000-8FAB4D14-2092-4D50-8F29-42D11CC4E8BAQ33509292-F2068476-C0E7-4088-AC72-3727DB060BC2Q33557015-2AB38C77-1333-4D7B-A2EB-78DAE04443A5Q33586493-080BF7E4-85E7-4579-8AC8-67CD5C434D53Q33593858-723D0685-762F-4418-A758-96C0074EBCD9Q33688872-BECE89DB-BDC3-4EA2-86B0-E39269289209Q33718737-F5C404F6-2C8E-46C5-9D59-155CE09852B0Q33732210-ED621057-22B6-4A6A-9704-B3DC03EF4626Q33746583-47B9DA7C-C636-4A45-B9B2-9774B659300EQ33779875-BAAC7038-E68F-46D7-AF2E-D9B0D8C5C983Q33805073-8431AD29-6AEC-4487-A864-1C9ADF00E5B4Q33959343-CABDD653-E461-44B1-AA8B-A03EDDBF553CQ33965681-F579B222-65E8-4D2A-AF06-0382997125D3Q34014497-93724AB9-E97D-443A-A32B-B2DC12D2977FQ34017616-998273A0-F139-45AF-9522-AB0054D160A2Q34048819-288B94FC-6F7B-4BFE-9842-01403DDF3211Q34071227-3E52A47F-962D-4E9E-85DA-577561F1D5DEQ34257887-2CEC3279-A295-4396-95E2-F0F6FC101877Q34257902-E311E617-0104-4B6B-AB58-5A87A8752429Q34405616-E8039275-A9A4-487B-91E8-F661EF7D4F21Q34422110-72A6492E-8DD7-47DF-899B-0D8AECBA6218Q34432692-D1DCE30F-531D-4704-A1D2-7CB015F4029EQ34458339-6CA48B99-832D-4943-8286-780472955374Q34511672-E45968C8-3062-403C-8E56-AC11EED7EFC6Q34541830-19FD7296-099C-41DD-9D2B-B42F9D7E8BC6Q34549227-5A5BF72E-B617-4C8B-BAC9-022F53607298
P2860
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Clinical activity and immune m ...... 0 agonist monoclonal antibody.
@en
type
label
Clinical activity and immune m ...... 0 agonist monoclonal antibody.
@en
prefLabel
Clinical activity and immune m ...... 0 agonist monoclonal antibody.
@en
P2093
P356
P1476
Clinical activity and immune m ...... 0 agonist monoclonal antibody.
@en
P2093
Amy Kramer
David L Bajor
J Joseph Mahany
Kelli L Running
Magi Khalil
Maryann Gallagher
Molly S Stumacher
Natalie A Hutnick
Patricia Sullivan
Peter J O'Dwyer
P304
P356
10.1200/JCO.2006.08.3311
P407
P577
2007-03-01T00:00:00Z